74 results about "Substantia nigra" patented technology

Cells derived from postpartum tissue such as the umbilical cord and placenta, pharmaceutical compositions comprising such cells, and methods for using such cells and pharmaceutical compositions to treat patients having a neurodegenerative condition of the substantia nigra or striatum, such as Parkinson's disease, are provided.

The invention relates to a medical image processing method, a device, a system and a storage medium. The method includes acquiring a detection image including an image of a substantia nigra region and/or a red nucleus region; Obtaining a segmentation neural network model, and performing segmentation operation on the detection image by adopting the segmentation neural network model to obtain a target mask image; obtaining a detection neural network model, and obtaiing the detection result by detecting the target mask image using the detection neural network model. This method can make more accurate detection results of detection images according to the trained detection neural network model, and further improve the accuracy of detection results.

The present invention pertains to the field of genomics and nanotechnology, specifically to the in vivo gene expression technologies and their application in gene therapy. It consists of the performance of the NTS-polyplex nanocomplex, which can carry nucleic acids to the neurons, involving neurotrophic therapy to treat neurodegenerative diseases. In particular, the present invention addresses the treatment of Parkinson's disease by the regulated expression of the BDNF neurotrophin.

Disclosed are methods and compositions for an animal model of Parkinson's disease. In particular, disclosed is the use of antisense compounds to inhibit the expression of ALDH1A1 in the substantia nigra of an animal brain for the purpose of creating an animal that will displays the symptoms of a human with Parkinson's Disease, including various biochemical, histological, and behavioral characteristics. Also disclosed are methods for using the animal model for Parkinson's disease to test potential therapeutic agents for Parkinson's disease.

An object of the present invention is to provide a model animal of Parkinson's disease comprising an α-synuclein gene introduced therein. The present invention provides a transgenic non-human mammal or a portion thereof, wherein an α-synuclein gene is introduced and the gene is expressed in neurons, and the number of dopamine-producing neurons in the substantial nigra is significantly decreased as compared with that of a wild-type animal.

The invention provides a metal-organic framework-superoxide dismutase assembly, a preparation method and an application thereof in preparation of drugs for treating Parkinson, and belongs to the technical field of biology. The framework makes use of biomimetic mineralization assembly strategy to immobilize SOD enzyme molecules into a metal-organic framework ZIF-8, coordination bonds are formed between SOD amino and zinc ions of ZIF-8, so that metal organic framework-SOD enzyme assembly (SOD@ZIF-8) are constructed based on enzymes. The temperature stability of SOD enzyme molecules and pH tolerance are improved through the frame work, by treating the SOD@ZIF-8 assembly as a therapeutic drug, at the cellular level, active oxygen produced by stimulation of MPP+ can be removed effectively, so as to relieve apoptosis caused by active oxygen; at the animal level, after intravenous chemotherapy by the assembly, the barrier in sports ability of Parkinson model mouse constructed by MPTP can be relieved, the expression level of tyrosine hydroxylase in substantia nigra is improved, the therapeutic effect is good.

The invention discloses an application of chlorogenic acid in preparation of medicines for treating a parkinson disease. The chlorogenic acid is beneficial to reduction of the toxicity of substantia nigra and striatum neurons and activation of the autophagy activity of substantia nigra and striatum neurons in a midbrain, beneficial to adjustment of blood ketone content of a parkinson disease mice model, and beneficial to inhibition of apoptosis of substantia nigra cells in the parkinson disease mice model, and plays positive improvement and treatment roles in symptoms, pathology and the like of the parkinson disease.

A comprehensive analytical method for predicting early-stage Parkinson's disease comprises the following steps: S1, reading diffusion weighted magnetic resonance data DW-MRI, carrying out noise reduction and pre-smoothing processing on all the data, carrying out modeling and imaging and fiber tracking by applying diffusion tensor imaging and high angular resolution diffusion imaging technologies to acquire voxel fiber direction information, and calculating six types of brain fiber variation analysis index data; S2, extracting and marking special brain region voxel information, selecting a continuous region as a midbrain substantia nigra region by virtue of setting a threshold value of an anisotropic fraction, and then screening and extracting the index data in interested regions; and S3, carrying out comprehensive analysis by applying a SPSS analytical tool according to the six types of brain fiber variation analysis index data obtained by the step S2 to obtain a fiber variation result on the midbrain substantia nigra regions of a testee and a normal person so as to predict the sickness status of the testee. The method provided by the invention is high in resolution and accurate and reliable.

The invention discloses a composition for promoting cell regeneration and a preparation method and use thereof. The composition for promoting cell regeneration provided by the invention is prepared by the following method: first, conducting in vitro culture of human bone marrow mesenchymal stem cells: adding a human stem cell growth factor, a granulocyte colony-stimulating factor and a clam extract, so that the human bone marrow mesenchymal stem cells can secrete a variety of human growth factors to form a human growth factor composition; and finally embedding the composition by a Water-in-Oil-in-Water (W / O / W) liposome embedding technology. The composition obtained by embedding can smear on epidermis to promote e wound healing of epidermal tissue, reduce scar formation, and activate hair follicle melanocytes and stimulate hair cell regeneration. In addition, the composition can be taken orally to promote regeneration and repair of damaged brain substantia nigra cells and hippocampal gyrus neurogenesis, and stimulate the proliferation of bone marrow hematopoietic stem cells.

The serial medicine carriers are named polypeptide mediated penetrating vector and belongs to membrane penetrating peptide family. They have the functions of penetrating cell membrane and cytoblast membrane, and may carry medicine molecule to penetrate physiological barriers, such as cell membrane, blood brain barrier, placenta barrier, etc. The new carrier-tyrosinie hydrozylase fusion protein is one new kind of protein with the features of both new carrier and tyrosinie hydrozylase, and it may reach human brain substantia nigra pathologic change part via blood brain barrier to treat parkinsonism.

The invention relates to a Parkinson's disease diagnosis device and method based on artificial intelligence. The device may include an image acquisition part that acquires a first image related to a multi-echo size and phase from nuclear magnetic resonance imaging in which a brain of a patient is imaged; an image processing part that performs post-processing on the acquired first image so as to enable the observation of a blackness and a blackbody-1 region serving as an image biomarker for Parkinson's disease; an image analysis unit that classifies a second image including a blackbody-1 regionby analyzing the post-processed first image, and detects the blackbody-1 region from the classified second image; and a diagnosis part that diagnoses whether or not the patient has suffered from Parkinson's disease by analyzing whether or not the detected blackbody-1 region is normal.

A method of treating a movement disorder in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of cells capable of modifying a neuronal discharge of the subject, thereby treating the movement disorder in the subject, wherein said administering is effected at a site selected from the group consisting of internal globus pallidus, subthalamic nucleus and substantia nigra pars reticulate.

The invention relates to a preparation method of a common traditional Chinese medicine of a fructus forsythiae active site. The method comprises: pulverizing a medicinal material of fructus forsythia; performing reflux extraction with a solvent, such as water or ethanol; concentrating the extracting liquid at a reduced pressure to obtain extractum; performing extraction through a plurality of organic solvents and recycling the organic solvents of the site extracted by n-butyl alcohol; dispersing and dissolving the site extracted by n-butyl alcohol in a proper amount of distilled water; taking the obtained supernate out and putting the supernate in a macroporous adsorption resin with weak polarity or medium polarity; and performing elution in a water-alcohol system to obtain the fructus forsythiae active site. According to the method, a separation method and a modern spectroscopic analysis method for a plurality of chemical components are utilized to separate and identify chemical components in the active site, thereby obtaining 15 compounds, 9 of which are new compounds. In vitro, the fructus forsythiae active site has an obvious function of preventing neurocyte damage due to rotenone, and in vivo, the fructus forsythiae active site can significantly increase the number of TH positive neuron, due to rotenone, of a substantia nigra zona compact of a rat and improve a Parkinson symptom of the rat. Therefore, the fructus forsythiae active site can be prepared into a medicine for preventing and curing the Parkinson disease.

The invention relates to an application of Lf (lactoferrin) in preparation of PD (Parkinson's disease) treating drugs. The drugs are used for treating or preventing a toxicological action of MPTP (1-methyl-4-phenyl-1,2 ,3 ,6-tetrahydropyridine), the Lf is APO-Lf or HOLO-Lf, the two drugs both can reduce the level of iron in substantia nigra in the brain and play a neuroprotective effect on a patient with PD, APO-Lf and HOLO-Lf have no influence on peripheral iron level, neither are chelated with iron to result in anemia, nor increase iron to cause iron loading. In one embodiment, the Lf is APO-Lf or HOLO-Lf.

The invention provides a neural organoid comprising a multi-module structure capable of simulating a substantia nigra-striatum pathway in vitro, and a method for preparing the neural organoid. The invention further provides application of the neural organoid in disease research, drug screening, intracerebral transplantation and the like.

The invention relates to the technical field of pharmaceutics and discloses the application of the compound AM-1241, namely (R,S)-3-(2-iodo-5-nitrobenzene formyl)-1-(1-methyl-2-piperidinyl methyl)-1H-indol to preparation of a drug for treating Parkinson's disease. According to the compound, a cannabinoid receptor CB2 is used as the effective target spot of Parkinson's disease treatment, and symptoms of Parkinson's disease can be relieved greatly; furthermore, a molecular mechanism shows that CB2 expression of substantia nigra and hippocampus are activated, the occurrence rate of neuronal apoptosis is reduced, and a remarkable neuroprotective effect is realized; besides, by preparing the compound into solid lipid nanoparticle preparations for administration, drug absorption rate and brain-targeting effect can be improved, so that Parkinson's disease treatment effect is further improved. It is expected to prepare the drug for treating Parkinson's disease with the compound as the effective constituent, and the drug can become the substitution of existing levodopa drugs.

The invention belongs to the technical field of detection and analysis, and relates to a method for analyzing Parkinson disease therapeutic effects. The method comprises the following steps of: selecting adult rats and living under room temperature condition, and selecting haloperidol as the medicine; selecting an animal brain three-dimensional position finder; dividing the rats into two groups, namely, a reference group and an XE991 group; in the state that the rats are conscious and act freely, carrying out intraperitoneal injection of haloperidol, and subsequently injecting normal saline or XE991 into substantia nigra through a metal casing; observing whether the heads of the rats deflect or not and observing the deflection directions and the angles, and scoring according to the head-back straight lines of the rats and the included angles of the back-tail straight lines; slightly putting the front legs of the rats on a metal rod so as to record the rigidity incubation periods of the double front legs of the rats on the metal rods, wherein the test results show that the XE991 has the therapeutic effect on the PD (Parkinson's Disease) rigid rats induced by haloperidol, thereby realizing the analysis on the Parkinson's disease therapeutic effects. The method is simple in detection and analysis process and reliable in principle, the used equipment and instruments are developed in techniques, the detection data are accurate and the detection is environment-friendly.

The invention provides a medicine for improving the activity of midbrain substantia nigra dopamine neurons to preventing a Parkinson disease. The medicine is fulvestrant. The invention also provides amethod for screening the medicine for improving the activity of midbrain substantia nigra dopamine neurons to preventing the Parkinson disease. A bioinformatics method using a weighted gene co-expression network to analyze and identify a biologically-related differential co-expression module, matches genes closely related to the Parkinson disease to a gene network module so as to obtain a gene co-expression module related to the Parkinson disease, and by a correlation map database and different gene expression profile data between midbrain substantia nigra encephalic region samples in a normal control group from a Parkinson patient, screens out a medicine that can significantly reverse the abnormally expressed genes in the module. The method overcomes the limitation of a single pathway ortarget, and also uses the CMAP database to screen approved clinical medicines, saves time, money, and labor costs, and is more conducive to the development of safe and effective medicines.